Kornimate/medical-research-clean huggingface dataset:
the effects of the inspiratory muscle plus aerobic training compare to aerobic training alone in heart failure patients.

Conditions: Heart Failure

Summary: this study aims to compare effects of inspiratory muscle training added by aerobic training to aerobic training alone in heart failure patients with inspiratory muscle weakness. to do so, strength and endurance of inspiratory muscles, functional capacity, quality of life, heart rate variability and sleep apnea evaluations will be conducted in patients with heart failure.

a sample comprising at least 30 individuals is necessary. these subjects will be randomized in two groups, one consisting of inspiratory muscle training plus aerobic training, whereas the other will consist of the aerobic training alone. this prospective, randomized, controlled trial will include patients with the diagnosis of chronic heart failure attributable to left ventricular systolic dysfunction who will be recruited from the heart failure clinic. entry criteria for the study are a previous history of symptomatic heart failure caused by left ventricular systolic dysfunction, inspiratory muscle weakness (pimax \< 70% of the predicted), and clinical stability, including no change in medications for the past three months. exclusion criteria will be unstable angina, myocardial infarction, or cardiac surgery within the previous three months, chronic metabolic, orthopedic, or infectious diseases, treatments with steroids, hormones, or cancer chemotherapy, history of exercise-induced asthma, chronic obstructive pulmonary disease and smokers will be not recruited. the protocol was approved by the committee for ethics in research of hospital de clinics de porto alegre and ijuí university and all subjects are required to sign an informed consent form. variables will be measured by strength and endurance (progressive and constant load), 6-min walk test, cardiopulmonary exercise testing, quality of life questionnaire, evaluation of the heart rate variability and sleep apnea. the inspiratory muscle training plus aerobic training will consist of cycle exercise (3 sessions/week) and inspiratory exercise by using threshold equipment for 30 min, 7 times per week, whereas aerobic training group will perform only cycle exercise. both treatments will last 12 weeks.

Eligibility criteria:
inclusion criteria: * previous history of symptomatic heart failure caused by left ventricular systolic dysfunction * inspiratory muscle weakness (pimax \< 70% of the predicted) * clinical stability, including no change in medications for the past three months exclusion criteria: * unstable angina * myocardial infarction, or cardiac surgery within the previous three months * chronic metabolic, orthopedic, or infectious diseases * treatments with steroids, hormones, or cancer chemotherapy * history of exercise-induced asthma, chronic obstructive pulmonary disease * smokers

Keywords: heart failure systolic dysfunction inspiratory muscle weakness
effect of the involvement of a medical clown on the labor experience

Conditions: Affective Symptoms

Summary: the experience of labor for a woman can be rewarding but can be traumatic. medical clowning may alleviate the potential for trauma.

the investigators plan to administer questionnaires to women who will agree to host a clown during their labor and to compare the feedback to those from women who did not.

Eligibility criteria:
inclusion criteria: singleton pregnancy, older than 18 years, younger than 40 years, uncomplicated pregnancy exclusion criteria: pregnancy complicated by pet, premature contractions muktiple pregnancy, older than 40 years, younger than 18 years
observational study of azilsartan/chlorthalidone and irbesartan/hydrochlorothiazide in hypertension and obesity.

Conditions: Arterial Hypertension

Summary: this is an observational prospective study of azilsartan medoxomil / chlorthalidone compared with irbesartan / hydrochlorothiazide in routine therapy of patients with arterial hypertension and obesity.

observational prospective study of azilsartan medoxomil/ chlorthalidone compared with irbesartan/hydrochlorothiazide combination therapy in patients with arterial hypertension and obesity in routine clinical practice (puzzle). the study population is 94 patients with untreated or poorly controlled arterial hypertension and obesity. the main inclusion criteria are: 1. male and female 35-55 year old. 2. diagnosis of essential arterial hypertension i-ii grade. 3. patients with obesity (bmi ≥ 30 kg/m²) 4. patients with untreated arterial hypertension (clinic sbp ≥ 140 mmhg, dbp ≥ 90 mmhg and no previous antihypertensive treatment. 5. patients with poorly controlled arterial hypertension (clinic sbp ≥ 140 mmhg, dbp ≥ 90 mmhg on previous antihypertensive treatment. 6. written informed consent. the main exclusion criteria are: 1. patients with symptomatic organ damage (myocardial infarction, stroke, angina pectoris, chronic kidney disease ≥ 4 grade, diabetes). 2. patients with secondary arterial hypertension. 3. patients with intolerance of angiotensin ii receptor blockers, thiazide diuretic. 4. patients with contraindication to study drugs in accordance with russian instruction. 5. patients currently enrolled in other clinical trials. the treatment period is 6 months. the study plan includes 4 basic and 1 additional visits are planned: initial visit, 3 follow-ups (including additional) and study-end visit.

Eligibility criteria:
inclusion criteria: 1. male and female 35-55 year old, 2. diagnosis of i-ii grade essential ah, 3. patients with obesity (bmi ≥ 30 kg/m²), 4. patients with untreated ah (office sbp ≥ 140 mmhg, dbp ≥ 90 mmhg, no previous antihypertensive therapy), 5. patients with poorly controlled ah (office sbp ≥ 140 mmhg, dbp ≥ 90 mmhg on previous antihypertensive therapy), 6. written informed consent form (icf). exclusion criteria: 1. patients with symptomatic organ damage (myocardial infarction, stroke, angina pectoris, chronic kidney disease stage ≥ 4, diabetes), 2. patients with intolerance of arb, thiazide diuretics, 3. secondary ah, 4. patients with contraindication to study drugs in accordance with russian instruction, 5. patients currently enrolled in other clinical trials.

Keywords: obesity
risk identification factors for pulmonary function impairment in aids patients recovered from severe pneumonia

Conditions: AIDS; Pneumonia

Summary: screening for risk factors related to lung function impairment in patients who have recovered from aids with severe pneumonia, to provide clinical evidence for early identification and intervention of lung function damage in this population.

this is a prospective, single-center, non-randomized, clinical observational cohort study. it involves monitoring lung function at discharge (baseline, 0w), and at the 4th, 8th, 12th, 24th, and 48th weeks in patients recovering from severe pneumonia with aids. basic demographic data, hiv rna quantification, routine blood tests, blood biochemistry, arterial blood gas results, oxygenation index, immune function (cd3+, cd4+, cd8+ t cell counts), and imaging studies are also collected. multifactorial logistic regression analysis is used to screen for clinical predictors of lung function decline in patients recovering from severe pneumonia

Eligibility criteria:
inclusion criteria: 1. confirmed hiv infection; 2. progression to the aids stage: cd4+ count \<200 cells/µl and/or occurrence of opportunistic infections associated with aids; 3. age between 18 to 65 years; 4. meet the diagnostic criteria for severe pneumonia, with reference to the 2021 treatment guidelines for community-acquired pneumonia developed by the american thoracic society (ats) and the infectious diseases society of america (idsa). exclusion criteria: 1. concurrent central nervous system lesions, severe liver disease, or cirrhosis; 2. concurrent aids-related or non-related tumors; 3. women who are pregnant or breastfeeding; 4. presence of serious underlying diseases such as heart, lung, liver, kidney, etc.; 5. alcohol abuse or drug use; 6. the researcher believes that the overall condition of the subject affects the evaluation and completion of the trial

Keywords: aids severe pneumonia lung function predictive factors
symptom-adapted physical activity intervention in minimizing physical function decline in older patients with acute myeloid leukemia undergoing chemotherapy

Conditions: Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Recurrent Adult Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia

Summary: this is a randomized clinical trial that studies symptom-adapted physical activity intervention in minimizing physical function decline in older patients with acute myeloid leukemia (aml) undergoing chemotherapy. physical activity may help decrease functional impairment and improve the quality of life in patients with aml undergoing chemotherapy.

primary objectives: i. to evaluate the feasibility of conducting a symptom-adapted, randomized behavioral intervention designed to improve physical function in older adults receiving chemotherapy for aml. ii. to estimate the effect size of the physical activity intervention on change in an objective measure of physical function, sppb (short physical performance battery). secondary objectives: i. to estimate the effects of the physical activity intervention on self-reported physical function, health-related quality of life, and symptoms (depression, distress, fatigue). outline: patients are randomized to 1 of 2 treatment arms. arm i: patients participate in an orientation session introducing the exercise program and protocol, reviewing fundamental principles, and demonstrating each activity. patients also receive educational materials to facilitate orientation and adherence. patients are offered 20-50 minute standard, intermediate, and/or low intensity physical activity sessions 5 days a week for 4 weeks. patients also receive lifestyle-related counseling for 20-30 minutes once weekly. arm ii: patients undergo usual care for 4 weeks. after completion of study treatment, patients are followed up every two weeks for two months and then monthly until week 24.

Eligibility criteria:
inclusion criteria: * diagnosis of aml with pathologic confirmation by world health organization (who) criteria * planned induction chemotherapy * absence of active medical problems that preclude participation in exercise (including, but not limited to: bleeding, acute thrombosis, ischemia, hemodynamic instability, uncontrolled pain) * patient must be ambulatory or able to walk with a cane * patients must have limited cognitive deficits (\< 3 incorrect responses on the pfeiffer mental status scale) * adequate english skills to understand and complete questionnaires * ability to understand and the willingness to sign a written informed consent document exclusion criteria: * presence of active medical conditions precluding participation to exercise (e.g., ischemia, bleeding, thrombosis, uncontrolled pain, hemodynamic instability) * inability to ambulate
trial of maintenance suo11248 versus placebo post chemotherapy for patients with advanced urothelial carcinoma

Conditions: Bladder Cancer

Summary: this study is a randomized, blinded, placebo-controlled study evaluating the drug, suo11248 (sutent), for maintenance therapy in advanced urothelial cancer.


Eligibility criteria:
inclusion criteria: * histologic/cytologic diagnosis of urothelial carcinoma (transitional cell carcinoma either pure or mixed histology) * all patients must have received four - six cycles of standard first line chemotherapy (protocol details suggested combinations) for treatment of locally recurrent or metastatic disease and must have achieved stable disease (sd), partial response (pr), or complete response (cr) to this chemotherapy. * type of response, number of cycles and specific regimen given must be carefully recorded and submitted at time of registration. * reports from pre and post treatment imaging will be required at time of registration to document response. * patients must be registered within 1 month (or the next business day if falls on a weekend or holiday) of scans demonstrating stable disease or better and no more than 42 days after receiving the last standard chemotherapy dose. for example, if patients are receiving treatment on days 1 and 8 of each cycle, day 8 of the last cycle would be considered the last standard chemotherapy dose. * patients may have received previous adjuvant or neoadjuvant therapy. * no prior antiangiogenic therapy for this stage of the disease. exclusion criteria: * major surgery within 4 weeks of starting the study treatment. * nci ctcae grade 3 hemorrhage or higher within 4 weeks of starting the study treatment. * history of or known spinal cord compression, or carcinomatous meningitis, or evidence of symptomatic brain or leptomeningeal disease on screening ct or mri scan. however treated, stable and asymptomatic brain metastases are allowed. * known hiv - positive patients may not participate. this is to avoid additional complications that immune suppression and hiv infection may cause due to the intense nature of the chemotherapy in this trial. * any of the following within 6 months prior to study administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure (chf), cerebrovascular accident or transient ischemic attack, or pulmonary embolism. * patients with history of or who are suspected to have chf can be included as long as they are asymptomatic and have an ejection fraction that is equal to or above the institutional lower limit of normal by baseline muga(obtained within one month of registration or the next business day if falls on a weekend or holiday). * ongoing cardiac dysrhythmias of nci ctcae grade \> 2. * unresolved bacterial infection. * uncontrolled hypertension. * pre-existing thyroid abnormality that can not be controlled medically. * concurrent treatment on another clinical trial. * pregnant or breast-feeding
combined amniotic membrane and platelet rich plasma clot for management of central corneal perforation

Conditions: Corneal Perforation

Summary: use of amniotic membrane(amt) and platelet rich plasma (prp) clot for closure of central corneal perforation

use of amniotic membrane and platelet rich plasma clot for closure of central corneal perforation either post infective or posttraumatic

Eligibility criteria:
inclusion criteria: * central corneal perforation exclusion criteria: * active infection * posterior segment pathology * non seeing eye
cannabioids as a new intervention for amphetamine dependence

Conditions: Amphetamine Addiction

Summary: addiction to amphetamine is characterized by alternating phases of intoxication and short abstinence, followed by recurrent drug-craving episodes which result in distress and relapse. addiction involves a number of neurotransmission systems, including the endocannabinoid system (ecbs). it has been demonstarted that cannabidioids can have physiological, anxiolytic and neuroprotective properties. it has been shown to have multiple therapeutic properties for treating anxiety, schizophrenia and interestingly cannabinoids have been shown to be potentially helpful in treating addiction, due to their effects on various neuronal circuits involved in this disorder. the investigators overall hypothesis is that cannabinoids are an interesting pharmacological contender to decrease amphetamine craving and treat amphetamine addiction.


Eligibility criteria:
inclusion criteria: * current dsm-v criteria for amphetamine use disorder * ability to give valid, informed consent exclusion criteria: * severe and/or unstable hepatic, neurologic (including diagnosis of seizures), cardiac (including arrhythmias) or renal disease, or any other severe or unstable medical condition that precludes safe participation in the study according to the study physician. * severe psychiatric condition (history of schizophrenia, schizoaffective disorder or bipolar disorder; current acute psychosis, mania or severe suicidality * any serious medical condition or psychiatric illness that precludes the subject from signing the informed consent form

Keywords: amphetamine cannabinoids
the severity of periodontitis at the buccal and palatal site

Conditions: Periodontal Diseases

Summary: to record and compare the periodontal conditions of buccal and palatal sites in patients


Eligibility criteria:
inclusion criteria: * patients with diagnosed periodontitis exclusion criteria: * compromised systematic health (uncontrolled hypertension, diabetes, impaired bone metabolism condition, etc.), uncontrolled periodontal disease, smoking \> 20 cigarettes/day or recent chemotherapy/radiotherapy in the oral and maxillofacial regions
using ferumoxytol-enhanced mri to measure inflammation in patients with brain tumors or other conditions of the cns

Conditions: Brain Injury; Central Nervous System Degenerative Disorder; Central Nervous System Infectious Disorder; Central Nervous System Vascular Malformation; Hemorrhagic Cerebrovascular Accident; Ischemic Cerebrovascular Accident; Primary Brain Neoplasm; Brain Cancer; Brain Tumors

Summary: this pilot clinical trial study will assess the inflammatory response of brain tumors or other central nervous system conditions in pediatric and adult patients using ferumoxytol-enhanced mri. imaging features will be correlated with the number of inflammatory cells (macrophages) at histopathology. determining the extent of inflammation associated with pathologies in the central nervous system may be helpful for diagnostic and prognostic purposes as well as monitoring treatment response of current and future immunotherapies.

in this study, we will establish the mr imaging characteristics of macrophages in malignant brain tumors and other cns conditions in the pediatric and adult populations using ferumoxytol, an ultrasmall superparamagnetic iron oxide (uspio) particle that is approved for the treatment of iron deficiency anemia in patients with chronic kidney disease. the investigators will correlate the mr signal of ferumoxytol uptake with the number of macrophages in surgical specimen at histopathology. this information may potentially offer clinicians a new means for risk stratification and monitoring treatment efficacy.

Eligibility criteria:
inclusion criteria: * any patient with suspected brain tumor diagnosed by mri * patients undergoing neuro-imaging evaluation by the neurosurgical service for other indications (e.g. vascular malformations, traumatic brain injury, ischemic and hemorrhagic stroke, cns infections, and neuro-degenerative diseases) exclusion criteria: * informed consent cannot be obtained either from the patient or legal representative * severe coexisting or terminal systemic disease that limits life expectancy or that may interfere with the conduct of the study * contraindication to mri (metal implants) * hemosiderosis/hemochromatosis * need for sedation or anesthesia (claustrophobia) that will not otherwise be undertaken as part of routine clinical care (e.g. routine mri under sedation already planned) * known hypersensitivity to feraheme (ferumoxytol) or any of its components * iron overload from any cause (not just hemosiderosis or hemochromatosis), even if secondary to frequent blood transfusions, severe chronic hemolysis, excess dietary or parenteral iron, or any other etiology
effect of acetazolamide on subclinical high-altitude pulmonary edema detected by lung ultrasonography

Conditions: High Altitude Pulmonary Edema

Summary: the overall goal of this study is to detect preclinical signs of hape by lung ultrasonography and evaluate the effectiveness of acetazolamide at decreasing pulmonary edema by using ultrasound.


Eligibility criteria:
inclusion criteria: 1. at least 18 years of age 2. able to consent 3. english speaking 4. trekking directly to everest base camp exclusion criteria: 1. age less than 18 years 2. non-english speaking 3. pregnant 4. already had a diagnosis of acute mountain sickness, high-altitude cerebral edema, or high-altitude pulmonary edema 5. been on a high-altitude trek 2 weeks prior to this study 6. has taken acetazolamide 1 week prior to start of trek 7. has a sulfa allergy 8. has any type of acute or chronic pulmonary conditions

Keywords: acetazolamide high-altitude illness high-altitude pulmonary edema lung comets lung ultrasound subclinical high-altitude pulmonary edema
tolerability of three local anesthetic formulations in conjunction with ngx-4010 for the treatment of neuropathic pain

Conditions: Herpes Zoster; Neuralgia; Pain; HIV Infections; Peripheral Nervous System Diseases; Diabetic Neuropathies; Diabetes Mellitus; Polyneuropathies

Summary: this study is a randomized, open-label multi-center evaluation of the tolerability of treatment with ngx-4010 in conjunction with pre-patch topical application of one of three 4% lidocaine-based local anesthetic products. eligible subjects will have moderate to severe neuropathic pain secondary to painful diabetic neuropathy (pdn), postherpetic neuralgia (phn) or hiv-associated neuropathy (hiv-an), with average numeric pain rating scale (nprs) scores during screening of 3 to 8 (inclusive).


Eligibility criteria:
key eligibility criteria: * must have had for at least 3 months painful diabetic neuropathy, or postherpetic neuralgia, or painful hiv-associated neuropathy, with moderate to severe pain on average. * must not have significant pain due to other causes (for example, arthritis). * must have intact skin at the treatment area. * must be prepared to remain on the same pain medications at the same doses as before the study for the entire duration of the study (12 weeks). * must not use topical pain medications on painful areas. * must be able to comply with study requirements such as completing daily pain diary and attending study visits and refrain from extensive travel during study participation. * must be at least 18 years old, not pregnant, and able to take care of self independently, with only occasional assistance if needed. * no significant medical problems of the heart, kidneys, liver or lungs, or cancer. * no history or current problem with substance abuse.

Keywords: dermal assessment pain assessment diary analgesics capsaicin herpes zoster neuralgia hiv infections peripheral nervous system diseases diabetic neuropathies diabetes mellitus polyneuropathies complementary therapies